Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Chronic Kidney Disease and Covid-19 Infection: A Case–Control Study Publisher



Moeinzadeh F1, 4 ; Mortazavi M1, 4 ; Shahidi S1, 4 ; Mansourian M2 ; Yazdani A3 ; Zamani Z1, 4 ; Seirafian S1, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Epidemiology and Biostatics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Biostatics and Public Health, Faculty of Health, Kashan University of Medical Sciences, Kashan, Iran
  4. 4. Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Advanced Biomedical Research Published:2022


Abstract

Background: To organize efforts to manage the coronavirus disease 2019 (COVID-19), it is necessary to understand which groups are at higher risk of infection. Kidney disease seems to be substantial in COVID-19 patients, but there are limited data on COVID-19 incidence and fatality among chronic kidney disease (CKD) patients. In this study, we intend to examine the association between CKD and susceptibility to COVID-19 infection. Materials and Methods: Participants were selected from those recruited in a population-based cross-sectional survey of CKD prevalence and associated risk factors in Iranian people 18 years and older. A three-part questionnaire was used for COVID-19 infection clinical symptoms and epidemiologic and hospitalization data. Results: A total of 962 individuals including 403 CKD patients and 559 healthy controls were recruited in this study. Healthy controls were suffering more from common cold signs, cough, fever, sore throat, headache, anosmia, dyspnea, and abdominal pain (all P < 0.05). Furthermore, the number of healthy individuals with myalgia was marginally higher compared to the CKD patients (P = 0.057). Data regarding the number of CKD patients with/without COVID-19 infection throughout different CKD stages revealed that there was no significant difference between the two groups in terms of COVID-19 infection in different stages of CKD (P = 0.956). Conclusion: We found that some of the clinical presentations of COVID-19 including common cold symptoms, cough, fever, sore throat, headache, anosmia, dyspnea, and abdominal pain were higher among healthy individuals compared to the CKD group. On the other hand, the susceptibility to COVID-19 infection was not significantly different in various early stages of CKD. © 2022 Advanced Biomedical Research.
Other Related Docs
13. Anticoagulation Therapy in Covid-19 Patients With Chronic Kidney Disease, Journal of Research in Medical Sciences (2021)
14. Isfahan Covid Cohort Study: Rationale, Methodology, and Initial Results, Journal of Research in Medical Sciences (2022)
28. Cancer Care Management During the Covid-19 Pandemic, Risk Management and Healthcare Policy (2020)
29. Cytokines and Micrornas in Sars-Cov-2: What Do We Know?, Molecular Therapy Nucleic Acids (2022)
42. Clinical Display, Diagnostics and Genetic Implication of Novel Coronavirus (Covid-19) Epidemic, European Review for Medical and Pharmacological Sciences (2020)
44. Sars-Cov-2 (Covid-19): New Discoveries and Current Challenges, Applied Sciences (Switzerland) (2020)